The overall goal of this UT MDACC SPORE is to facilitate innovative research in the prevention, detection, and treatment of ovarian cancer leading to the elimination of this disease as a major health problem. Our Cancer Center contains a unique concentration of talented investigators who are dedicated to clinical, translational, and funda mental ovarian cancer research. Multi-disciplinary care is provided to a large number of patients. For this SPORE, we have assembled an exceptional group of investigators from nine Universities complement ing the faculty at MDACC. Our institution has given high priority to the Sandra G. Davis Ovarian Cancer Research Program through recruitment, salary supports, clinical facilities, laboratory space and philanthropic funds. Over the last three years, the Program has instituted faculty recruitment, strengthened the research infrastructure, and funded seven pilot projects. We are now poised to take advantage of the rapid increase in the understanding of ovarian cancer at a molecular and cellular level. Funding of this SPORE will enhance our ability to translate insights from ovarian cancer biology to more effective prevention, detection, and treatment of ovarian cancer. The SPORE includes four projects that deal with (1) chemoprevention of ovarian cancer, (2) anti-angiogenesis therapy, (3) therapy with E1A, and (5) PI3 kinase as a target for therapy. Three Cores (Administra tion, Biostatistics and Pathology) will facilitate completion of the proposed projects. Career development funds will further strengthen our faculty and pilot projects will provide preliminary data for peer-reviewed funding. This SPORE will provide a critical component of a larger effort to develop effective strategies for chemoprevention, early detection, molecular profiling and therapeutics, bio- immunotherapy, high dose therapy, individualized therapy, supportive care, and community awareness.
| Nagaraja, Archana S; Dood, Robert L; Armaiz-Pena, Guillermo et al. (2018) Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 3: |
| Seo, Hyeonglim; Choi, Ikjang; Whiting, Nicholas et al. (2018) Hyperpolarized Porous Silicon Nanoparticles: Potential Theragnostic Material for 29 Si Magnetic Resonance Imaging. Chemphyschem 19:2143-2147 |
| Mitamura, T; Pradeep, S; McGuire, M et al. (2018) Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene 37:722-731 |
| Yuan, Jiao; Hu, Zhongyi; Mahal, Brandon A et al. (2018) Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 34:549-560.e9 |
| Liu, Xiaojun; Jiang, Yingjun; Nowak, Billie et al. (2018) Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. Cancer Chemother Pharmacol 81:255-267 |
| Haemmerle, Monika; Stone, Rebecca L; Menter, David G et al. (2018) The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 33:965-983 |
| Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242 |
| Umamaheswaran, Sujanitha; Dasari, Santosh K; Yang, Peiying et al. (2018) Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev 37:203-211 |
| Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742 |
| Huang, Yan; Hu, Wei; Huang, Jie et al. (2018) Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther 17:464-473 |
Showing the most recent 10 out of 648 publications
